Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prolastin-C in HIV
NCT01731691Phase 3Terminated
- Sponsor
- Institute for Human Genetics and Biochemistry
- Start
- Apr 2012
- Primary completion
- Jul 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of alpha1-proteinase inhibitor in human immunodeficiency virus infection (HIV) (3 arms), sponsored by Institute for Human Genetics and Biochemistry. Primary endpoints: CD4 Counts at 9 weeks, CD8 Counts at 9 weeks and 5 more. Started Apr 2012; status: terminated.
02
Drugs
alpha1-proteinase inhibitor
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT01731691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01731691.